Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04738630 | Unknown Phase 2

• 1 other identifier: HX008-II-NMIBC-01
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 5

Brief Summary

This is a single-arm, multicenter study to evaluate the efficacy and safety of HX008 injection in patients with BCG-unresponsive non-muscle invasive bladder cancer.

Conditions

Bladder Cancer

Outcome Measures

Primary Outcomes (2)

• Complete response (CR) rate

  up to approximately 24 months

• Event-free survival (EFS)

  up to approximately 36 months

Secondary Outcomes (6)

• Duration of response (DOR)

  up to approximately 36 months

• Event-free survival (EFS) in the Ta/T1 subset

  up to approximately 36 months

• Progression-free survival (PFS)

  up to approximately 36 months

• Recurrence free survival (RFS)

  up to approximately 36 months

• Overall survival (OS)

  up to approximately 36 months

Study Arms (1)

Experimental: HX008

EXPERIMENTAL

Participants will receive HX008 200 mg intravenous (IV) every 3 weeks (Q3W)

Drug: HX008

Interventions

HX008 DRUG

200 mg administered as IV infusion on Day 1 of each 21-day cycle.

Experimental: HX008

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be willing and able to provide written informed consent for the trial.
• Age ≥ 18 years old, male or female.
• Predominant histologic component (\> 50%) must be urothelial (transitional cell) carcinoma.
• Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Score.
• Histologically-confirmed diagnosis of high risk non-muscle invasive bladder cancer (T1, high grade Ta and/or carcinoma in situ \[CIS\]).
• BCG-unresponsive high risk non-muscle-invasive bladder cancer, BCG-unresponsive disease as defined as: (a) Persistent or recurrent CIS (+/- recurrent Ta/T1 disease) within 9 months of receiving adequate BCG (at least five of six doses doses of an initial induction course plus either at least two of three doses of maintenance therapy or at least two of six doses of a second induction course); or (b) Recurrent high-grade Ta/T1 disease within 9 months of completion of adequate BCG (at least five of six doses of an initial induction course plus either at least two of three doses of maintenance therapy or at least two of six doses of a second induction course).
• Patients must be deemed unfit for radical cystectomy by the treating physician or refuse radical cystectomy.
• All visible tumor must be completely resected 60 days prior to the first dose of trial treatment. Patients with T1 tumors must undergo a re-staging transurethral resection of bladder tumor (TURBT) within 6 weeks after initial TURBT, and re-staging TURBT must be 60 days prior to the first dose of trial treatment.
• All patients must have had a cystoscopy without papillary tumor and negative urinary cytology within 21 days prior to the first dose of trial treatment (positive cytology is allowed in patients with CIS component). A cystoscopy is not needed if the TURBT falls within 21 days of prior to the first dose of trial treatment.
• Patients must have had imaging with X-ray for chest, computed tomography (CT) or magnetic resonance imaging (MRI) for abdomen/pelvis within 90 days prior to the first dose of trial treatment demonstrating no evidence of metastasis.
• Willing to provide tissue specimens.
• Has adequate organ function as defined in the protocol.
• Male subjects must agree to use effective contraceptives during treatment and for at least 120 days after the last treatment.
• Women of childbearing age must have a negative pregnancy test within 72 hours before the first dose of trial treatment, and agree to use effective contraceptives during treatment and for at least 120 days after the last treatment.

You may not qualify if:

• Muscle-invasive or metastatic urothelial carcinoma.
• Concurrent extra-vesical (i.e., urethra, ureter, or renal pelvis) non-muscle invasive transitional cell carcinoma of the urothelium.
• Patients who had a malignant tumor other than urothelial carcinoma of the bladder within the first 5 years of enrolment. The following can be included: a. low-risk localized prostate cancer (staging ≤ T2B, Gleason score ≤7, PSA≤20ng/mL, no recurrence after treatment (as determined by PSA level)); b. low-risk prostate cancer (T1/ T2A, Gleason score ≤7, and PSA≤10ng/mL) who were not treated and under observation; c. patients with very low risk metastasis or death of malignant tumor (5-year metastasis or death risk\< 5%), showed no recurrence after standard treatment, such as cervical cancer in situ, basal or squamous cell skin cancer, etc.
• Has received prior therapy with an anti-PD-1, or anti-PD-L1, or anti-CTLA-4, or anti-4-1BB agents.
• Has received systemic chemotherapy or immunotherapy, or radiation therapy for bladder cancer.
• Patients with active autoimmune disease that has required systemic treatment in past 2 years.
• Has received a major surgery within 4 weeks prior to the first dose of trial treatment.
• Has a history of testing positive for human immunodeficiency virus (HIV), or known acquired immunodeficiency syndrome (AIDS), or stem cell transplantation or organ transplantation.
• Patients with active chronic hepatitis B or active hepatitis C. Patients with non-active HBsAg carriers, treated and stable hepatitis B (HBV DNA below the threshold of the test standard of each center), and cured hepatitis C can be enrolled.
• Has received system treatment with corticosteroids (dose \>10mg/day prednison or other therapeutic hormones) within 2 weeks prior to the first dose of trial treatment.
• Has a history of active tuberculosis.
• Has a history or current interstitial pneumonia, or current non--infectious pneumonitis.
• Has uncontrolled systemic disease, such as diabetes or hypertension.
• Has cardiac dysfunction (grade III-IV according to NYHA) and significant pulmonary disease (such as shortness of breath at rest or minor activity or the need for oxygen for any reason) prior to the first dose of trial treatment.
• Patients with other disease, or metabolic disorder, or abnormal physical examination or laboratory test, or anticipated to cause complications with trial treatment.

Sponsors & Collaborators

• Taizhou Hanzhong biomedical co. LTD: lead

Study Sites (5)

Union Hospital Affiliated to Tongji Medical College, Huazhong University of science and technology

Wuhan, Hubei, 430022, China

RECRUITING

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology

Wuhan, Hubei, 430030, China

RECRUITING

Hunan Cancer Hospital

Changsha, Hunan, 410000, China

RECRUITING

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Sichuan, 400016, China

RECRUITING

MeSH Terms

Conditions

Urinary Bladder Neoplasms

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Central Study Contacts

Dingwei Ye

CONTACT

34778299; dwyeli@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 31, 2021
• First Posted: February 4, 2021
• Study Start: September 25, 2020
• Primary Completion: December 1, 2022
• Study Completion: December 1, 2023
• Last Updated: February 4, 2021

Record last verified: 2021-01

Locations

CN (5)